Cancer Immunology, Immunotherapy : Impact Factor & More
eISSN: 1432-0851pISSN: 0340-7004
Share this on:
Key Metrics
CiteScore 
10
Impact Factor
5 - 10
SNIP
1.25
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Cancer Immunology, Immunotherapy Journal Specifications
Indexed in the following public directories
Web of Science 
Scopus 
SJR
| Overview | |
| Publisher | SPRINGER |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 1976 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Cancer Immunology, Immunotherapy ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Cancer Immunology, Immunotherapy
CD39/CD73-mediated immunosuppression and tumor aggressiveness in bladder cancer.
- 22 Apr 2026
- Cancer immunology, immunotherapy : CII
Neutral sphingomyelinases restrict natural killer cells activity against lung cancer.
- 22 Apr 2026
- Cancer immunology, immunotherapy : CII
Repurposing public sarcoma multi-omics for neoantigen discovery.
- 21 Apr 2026
- Cancer immunology, immunotherapy : CII
IL-18-armed oncolytic vaccinia virus remodels the suppressive microenvironment via macrophage and Treg modulation in lymphoma.
- 21 Apr 2026
- Cancer immunology, immunotherapy : CII
Identification and prioritisation of tumour antigen candidates from 79 glioblastoma transcriptomes.
- 21 Apr 2026
- Cancer immunology, immunotherapy : CII
Envafolimab combined with lenvatinib and albumin-bound paclitaxel in previously treated advanced gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: a prospective, phase II, multi-cohort trial.
- 21 Apr 2026
- Cancer immunology, immunotherapy : CII
CD39/CD73-mediated immunosuppression and tumor aggressiveness in bladder cancer.
- 22 Apr 2026
- Cancer immunology, immunotherapy : CII
Neutral sphingomyelinases restrict natural killer cells activity against lung cancer.
- 22 Apr 2026
- Cancer immunology, immunotherapy : CII
Repurposing public sarcoma multi-omics for neoantigen discovery.
- 21 Apr 2026
- Cancer immunology, immunotherapy : CII
IL-18-armed oncolytic vaccinia virus remodels the suppressive microenvironment via macrophage and Treg modulation in lymphoma.
- 21 Apr 2026
- Cancer immunology, immunotherapy : CII
Identification and prioritisation of tumour antigen candidates from 79 glioblastoma transcriptomes.
- 21 Apr 2026
- Cancer immunology, immunotherapy : CII
Envafolimab combined with lenvatinib and albumin-bound paclitaxel in previously treated advanced gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: a prospective, phase II, multi-cohort trial.
- 21 Apr 2026
- Cancer immunology, immunotherapy : CII
FAQs on Cancer Immunology, Immunotherapy
How long has Cancer Immunology, Immunotherapy been actively publishing? 
What is the publishing frequency of Cancer Immunology, Immunotherapy?
How many articles did Cancer Immunology, Immunotherapy publish last year?
What is the eISSN & pISSN for Cancer Immunology, Immunotherapy?
What is Citescore for Cancer Immunology, Immunotherapy?
What is SNIP score for Cancer Immunology, Immunotherapy?
Who is the publisher of Cancer Immunology, Immunotherapy?
Check if your manuscript is a good match for
undefined
Upload your manuscript to get recommendations of journals
that have published papers similar to your manuscript
Drag and drop your file here
We accept manuscripts in English. File format: .doc and .docx | Maximum size: 10 MB | Word count: 200-300,000 words | File length: less than 100 pages
Do not have a manuscript right now? Use an abstract or summary
Your document is 100% secure & confidential We use 256-bit encryption for total security and
ISO/IEC 27001:2013 Certified
What all does the report include
01. Degree of Match
02. Common Topics
03. Additional
Recommendations
Recommendations